Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Peggs, Karl S  [Clear All Filters]
2024
Webster AP, Ecker S, Moghul I, Liu X, Dhami P, Marzi S, Paul DS, Kuxhausen M, Lee SJ, Spellman SR, et al. Donor whole blood DNA methylation is not a strong predictor of acute graft host disease in unrelated donor allogeneic haematopoietic cell transplantation. Front Genet. 2024;15:1242636.
2021
Roddie C, Dias J, O'Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, Bosshard-Carter L, Mitsikakou M, Mehra V, Roddy H, et al. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2021:JCO2100917.
Marzolini MAV, Wilson AJ, Sanchez E, Carpenter B, Chakraverty R, Hough R, Kottaridis P, Morris EC, Thomson KJ, Peggs KS. Natural history of EBV replication and viral load dynamics after alemtuzumab based allogeneic stem cell transplantation. Transplant Cell Ther. 2021.
2019
Das-Gupta E, Thomson KJ, Bloor AJC, Clark AD, Mackinnon S, Kayani I, Clifton-Hadley L, Patrick P, El-Mehidi N, Lawrie A, et al. Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study. Blood Adv. 2019;3(24):4264-4270.
2018
Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs KS, Afanasyev B, Díez-Martín JL, Corradini P, et al. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer. 2018.